In ASCO arms race, Keytruda proves status as king of I-O

4 June 2018

There are plenty of immuno-oncology (I-O) drugs in development and Bristol-Myers Squibb’s (NYSE: BMY) Opdivo (nivolumab) is the current best-seller of those on the market, but Merck & Co (NYSE: MRK) has proven beyond doubt that it undoubtedly has the hottest asset in the space at the present time.

The US pharma giant has showcased new Phase III lung cancer data on Keytruda (pembrolizumab) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, the biggest stage in cancer drug development and traditionally the event to which companies bring their best study results.

Success with chemo combination

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK